dc.creator | Papanagnou P., Papadopoulos G.E., Stivarou T., Pappas A. | en |
dc.date.accessioned | 2023-01-31T09:43:49Z | |
dc.date.available | 2023-01-31T09:43:49Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.2147/OTT.S182685 | |
dc.identifier.issn | 11786930 | |
dc.identifier.uri | http://hdl.handle.net/11615/77758 | |
dc.description.abstract | Pleiotropy in biological systems and their targeting allows many pharmaceuticals to be used for multiple therapeutic purposes. Fully exploiting the therapeutic properties of drugs that are already marketed would be highly advantageous. This is especially the case in the field of oncology, where the ineffectiveness of typical anticancer agents is a common issue, while the development of novel anticancer agents is a costly and particularly time-consuming process. Octreotide and chloroquine are two pharmaceuticals that exhibit profound antitumorigenic activities. However, the current therapeutic use of octreotide is restricted primarily to the management of acromegaly and neuroendocrine tumors, both of which are rare medical conditions. Similarly, chloroquine is used mainly for the treatment of malaria, which is designated as a rare disease in Western countries. This limited exploitation contradicts the experimental findings of numerous studies outlining the possible expansion of the use of octreotide to include the treatment of common human malignancies and the repositioning of chloroquine in oncology. Herein, we review the current knowledge on the antitumor function of these two agents stemming from preclinical or clinical experimentation. In addition, we present in silico evidence on octreotide potentially binding to multiple Wnt-pathway components. This will hopefully aid in the design of new efficacious anticancer therapeutic regimens with minimal toxicity, which represents an enormous unmet demand in oncology. © 2019 Papanagnou et al. | en |
dc.language.iso | en | en |
dc.source | OncoTargets and Therapy | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059468709&doi=10.2147%2fOTT.S182685&partnerID=40&md5=51fc8bc3a3fa3b7d98a21899c23fb5d4 | |
dc.subject | beta catenin | en |
dc.subject | binding protein | en |
dc.subject | chloroquine | en |
dc.subject | dickkopf 1 protein | en |
dc.subject | Kremen1 protein | en |
dc.subject | Kremen2 protein | en |
dc.subject | low density lipoprotein receptor related protein 5 | en |
dc.subject | low density lipoprotein receptor related protein 6 | en |
dc.subject | octreotide | en |
dc.subject | protein p53 | en |
dc.subject | unclassified drug | en |
dc.subject | Wnt protein | en |
dc.subject | antineoplastic activity | en |
dc.subject | apoptosis | en |
dc.subject | Article | en |
dc.subject | drug marketing | en |
dc.subject | drug mechanism | en |
dc.subject | drug protein binding | en |
dc.subject | drug repositioning | en |
dc.subject | drug targeting | en |
dc.subject | evidence based medicine | en |
dc.subject | gastrointestinal tumor | en |
dc.subject | human | en |
dc.subject | in vitro study | en |
dc.subject | in vivo study | en |
dc.subject | liver tumor | en |
dc.subject | malignant pleura effusion | en |
dc.subject | nonhuman | en |
dc.subject | oncology | en |
dc.subject | outcome assessment | en |
dc.subject | prediction | en |
dc.subject | signal transduction | en |
dc.subject | Dove Medical Press Ltd. | en |
dc.title | Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: The use of octreotide and chloroquine in oncology | en |
dc.type | journalArticle | en |